These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 639833)

  • 21. Simultaneous GLC determination of clofibrate and clofibric acid in human plasma.
    Wolf MS; Zimmerman JJ
    J Pharm Sci; 1980 Jan; 69(1):92-3. PubMed ID: 7354454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the metabolism of clofibride, a hypolipaemic drug.
    Loiseau GP; Millischer RJ; Lohier PY; Mardiguian JS; Gilede AM; Ginocchio AV
    J Pharm Pharmacol; 1980 Jul; 32(7):483-8. PubMed ID: 6105184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
    Merk W; Graben N; Hartmann H; Nikolaus C; Schlierf G; Schwandt P
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):59-62. PubMed ID: 3557732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum clofibrate concentrations in patients on continuous medication.
    Faed EM; McQueen EG
    Pharmacology; 1974; 12(3):144-51. PubMed ID: 4475428
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics and bioavailability of simfibrate a new clofibric acid derivative.
    Harvengt C; Desager JP
    Curr Ther Res Clin Exp; 1976 Jan; 19(1):145-151. PubMed ID: 812660
    [No Abstract]   [Full Text] [Related]  

  • 26. Clofibrate disposition in renal failure and acute and chronic liver disease.
    Gugler R; Kürten JW; Jensen CJ; Klehr U; Hartlapp J
    Eur J Clin Pharmacol; 1979 Jun; 15(5):341-7. PubMed ID: 456406
    [No Abstract]   [Full Text] [Related]  

  • 27. Chlorophenoxyisobutyric acid derivatives and apolipoprotein B metabolism.
    Shepherd J; Packard CJ
    Monogr Atheroscler; 1985; 13():85-91. PubMed ID: 4088282
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.
    Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP
    Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.
    Männistö PT; Tuomisto J; Jounela A; Penttilä O
    Acta Pharmacol Toxicol (Copenh); 1975 Apr; 36(4):353-65. PubMed ID: 1093358
    [No Abstract]   [Full Text] [Related]  

  • 30. Bioavailability of plafibride in healthy volunteers.
    Santaniello E; Conti F; Vilageliu J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma half-life of clofibric acid in renal failure.
    Faed EM; McQueen EG
    Br J Clin Pharmacol; 1979 Apr; 7(4):407-10. PubMed ID: 444361
    [No Abstract]   [Full Text] [Related]  

  • 32. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
    Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
    J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypocholesterolaemia in the rat after p-chlorophenoxyisobutyric acid (CPIB) administration as a synthetic triglyceride, 1,3-dipalmitoyl 2(p-chlorophenoxyisobutyroyl)-rac-glycerol.
    Owen JS; Billimoria JD
    Clin Chim Acta; 1977 Sep; 79(2):349-56. PubMed ID: 890970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver.
    Hanefeld M; Kemmer C; Leonhardt W; Kunze KD; Jaross W; Haller H
    Atherosclerosis; 1980 Jun; 36(2):159-72. PubMed ID: 7406947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of clofibrate in patients with renal insufficiency.
    Viikari J; Anttila M; Kasanen A
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Stability of antilipidemic etofibrate and its metabolites towards gastrointestinal and blood hydrolases (author's transl)].
    Oelschläger H; Rothley D; Ewert M; Nachev P
    Arzneimittelforschung; 1980; 30(6):984-8. PubMed ID: 7191278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man.
    Houin G; Thébault JJ; D'Athis P; Tillement JP; Beaumont JL
    Eur J Clin Pharmacol; 1975 Aug; 8(6):433-7. PubMed ID: 1233245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition pharmacokinetics of bezafibrate in man.
    Abshagen U; Bablok W; Koch K; Lang PD; Schmidt HA; Senn M; Stork H
    Eur J Clin Pharmacol; 1979 Aug; 16(1):31-8. PubMed ID: 499297
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats.
    Cayen MN; Robinson WT; Dubuc J; Dvornik D
    Biochem Pharmacol; 1979 Apr; 28(7):1163-7. PubMed ID: 444274
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.